Population pharmacokinetics of levetiracetam in term neonates with hypoxic–ischemic encephalopathy and therapeutic hypothermia: The LEVNEONAT‐1 study
Abstract
Aim This study aimed to describe the pharmacokinetics (PK) of levetiracetam (LEV) in term neonates treated for neonatal seizures secondary to hypoxic–ischemic encephalopathy (HIE). Methods Fifteen neonates were included and received a loading dose ranging from 30 to 60 mg/kg followed by eight maintenance doses corresponding to one‐fourth of the loading dose every 8 h. Five blood PK samples were drawn for each neonate: three after the loading dose and two after the last maintenance dose. Data were analysed by a population approach using NONMEM software. The possible relationship between LEV Cmax and AUC from time 0 to 4 h after the loading dose (AUC 4h ) and the relative seizure difference (RSD) that defined the LEV efficacy was investigated by linear regression. Results LEV PK was described by a two‐compartment model with allometric scaling based on body weight. Typical values (%IIV) for LEV CL, central and peripheral distribution volume (Vc and Vp) and distribution clearance (Q) were 4.27 (15%) L/h, 46.5 (14%) L, 6.10 L (98%) and 1.75 L/h, respectively. Creatinine clearance (CLcr) and natremia were found to be significant covariates for LEV clearance (CL), CL increasing with CLcr and natremia. No relationship was found between LEV Cmax or AUC 4h and RSD. Conclusion A population PK model of LEV in term neonates with HIE was developed. The influence of natremia was highlighted for the first time and could reflect the relationship between the encephalopathy severity and LEV PK in this population.
Related
- CSF pharmacokinetics-pharmacodynamics of linezolid in critically brain injured patients, with or without central nervous system healthcare-associated infection. The PK-Pop-LCR Study: A Multicentre Pharmacokinetics and Pharmacodynamics Population Study
- Population pharmacokinetics of cefazolin administered as prophylaxis in paediatric patients undergoing cardiac surgery
- Traumatic Brain Injury induces persistent behavioural deficits that are rescued by the antiepileptic drug Levetiracetam
- JNJ-42153605, a mGluR2 PAM, potentiates Levetiracetam treatments of TBI to mitigate subsequent tau aggregation in a larval zebrafish model
- Combined lactate and hypothermia therapy enhances neuroprotection following neonatal hypoxic-ischemic brain injury
BibTeX
@article{mimram2026population,
title = {{Population pharmacokinetics of levetiracetam in term neonates with hypoxic–ischemic encephalopathy and therapeutic hypothermia: The LEVNEONAT‐1 study}},
author = {Léo Mimram and Moreno Ursino and Julie Leger and Emilie Bourrel-Ponchel and Florence Flamein and Alexandra Chadie and Isabelle Guellec and Sarah Zohar and Vincent Jullien and Géraldine Favrais},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
month = oct,
doi = {10.1002/bcp.70888},
url = {https://u-picardie.hal.science/hal-05836587v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Population pharmacokinetics of levetiracetam in term neonates with hypoxic–ischemic encephalopathy and therapeutic hypothermia: The LEVNEONAT‐1 study
AU - Léo Mimram
AU - Moreno Ursino
AU - Julie Leger
AU - Emilie Bourrel-Ponchel
AU - Florence Flamein
AU - Alexandra Chadie
AU - Isabelle Guellec
AU - Sarah Zohar
AU - Vincent Jullien
AU - Géraldine Favrais
PY - 2026
DA - 2026/10/20
JO - British Journal of Clinical Pharmacology
DO - 10.1002/bcp.70888
UR - https://u-picardie.hal.science/hal-05836587v1
AB - Aim This study aimed to describe the pharmacokinetics (PK) of levetiracetam (LEV) in term neonates treated for neonatal seizures secondary to hypoxic–ischemic encephalopathy (HIE). Methods Fifteen neonates were included and received a loading dose ranging from 30 to 60 mg/kg followed by eight maintenance doses corresponding to one‐fourth of the loading dose every 8 h. Five blood PK samples were drawn for each neonate: three after the loading dose and two after the last maintenance dose. Data were analysed by a population approach using NONMEM software. The possible relationship between LEV Cmax and AUC from time 0 to 4 h after the loading dose (AUC 4h ) and the relative seizure difference (RSD) that defined the LEV efficacy was investigated by linear regression. Results LEV PK was described by a two‐compartment model with allometric scaling based on body weight. Typical values (%IIV) for LEV CL, central and peripheral distribution volume (Vc and Vp) and distribution clearance (Q) were 4.27 (15%) L/h, 46.5 (14%) L, 6.10 L (98%) and 1.75 L/h, respectively. Creatinine clearance (CLcr) and natremia were found to be significant covariates for LEV clearance (CL), CL increasing with CLcr and natremia. No relationship was found between LEV Cmax or AUC 4h and RSD. Conclusion A population PK model of LEV in term neonates with HIE was developed. The influence of natremia was highlighted for the first time and could reflect the relationship between the encephalopathy severity and LEV PK in this population.
SN - 0306-5251
SN - 1365-2125
ER -